Vaxxinity

VAXX

Biotechnology · Healthcare

Price

$0.00

+0.00 (+0.00%)

Market Cap

$12,678

Exchange

Other OTC

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Vaxxinity is a biotechnology company that develops vaccines designed to treat chronic diseases rather than prevent infections. Instead of targeting viruses like flu or COVID, its medicines train the immune system to fight conditions like Alzheimer's disease, Parkinson's disease, and high cholesterol. The company's main customers would be patients and healthcare systems, and it sits in the emerging field of "therapeutic vaccines."

Vaxxinity earns no meaningful revenue yet, as its drug candidates are still in clinical trials and have not received regulatory approval. The company is based in the United States but has conducted trials across multiple countries. Its potential moat lies in its proprietary UB platform technology for generating immune responses against the body's own proteins, but the main risk is significant: the company is burning cash with no approved products, and failure in late-stage clinical trials could threaten its ability to continue operating without raising additional funds.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

YoY Growth Rate

Revenue data limited

EPS Growth

+43.8% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$34M/ year

↓ Declining (-29% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

52.5%ownership

Insiders own a meaningful stake in the company

Cash Runway

~7 months

$30M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Short runway — potential dilution ahead through share issuance

Cash watch

Vaxxinity has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Share count broadly stable

+0.8% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 125.5M (2019) → 126.5M (2023)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

-40.8%

Weak — -40.8% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

1.13

Elevated debt (1.13)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial